Trevi Therapeutics Secures $15,000,000 New Funding Round

  • Feed Type
  • Date
    1/8/2015
  • Company Name
    Trevi Therapeutics
  • Mailing Address
    195 Church Street 14th Floor New Haven, CT 06510 USA
  • Company Description
    Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions.
  • Website
    http://www.trevitherapeutics.com
  • Transaction Type
    Debt
  • Transaction Amount
    $15,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis.
  • M&A Terms
  • Venture Investor
  • Venture Investor

Trending on Xconomy